Norfolk research company plans clinical trials using medical marijuana
Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions.
Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer. The new venture potentially opens the door to significantly expanding national research being done on the medical benefits of cannabis. Read the full story here.
Stories you may be interested in
Insomnia: A Silent Epidemic
The struggle to get a good night’s sleep is something many adults can relate to, but what if there was a natural alternative to keep those sheep jumping all night long? CBD, also known as cannabidiol, has been gaining popularity among patients to help treat pain, anxiety and so much more. Additionally, conditions such as…
Read More 
After A Decade Of Testing, Israeli Medical Cannabis Comes To The US
Cannabis is still federally illegal, so while more than 30 US states allow doctors to recommend it, there is very little medical testing of the substance in America. In Israel however, medical cannabis has been legal for more than ten years and studies on the plant’s ability to alleviate the side-effects of cancer and ease…
Read More 
Three Key Voices in the Medical Marijuana Industry
As medical marijuana programs continue to expand throughout the United States, it is important to recognize some of the key voices throughout the industry that got us here. These individuals range from researches to physicians and even to patients who started their own advocacy group. Keep reading to learn about just three of the many…
Read More 
LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY
There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed. Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed…
Read More 
Older adults and medical marijuana: Reduced stigma and increased use
As a primary care doctor who has incorporated medical cannabis into his practice, it is notable how many silver-haired patients are coming in to discuss the pros and cons of a trial of medical cannabis. These patients range from people in their 60s with kidney failure who can no longer take certain pain medications but…
Read More 
CEO Spotlight: James West
As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More